Send us Fan Mail

In this special edition of the WTR Small‑Cap Spotlight Flashcast, Water Tower Research CEO and Co‑Founder Shawn Severson previews the WTR Insights Virtual Conference, April 14–15. The two‑day event features 24 small‑ and micro‑cap companies across ALL WTR research sectors. These companies represent more than $5.5B in combined market cap and will give investors direct access to C-Suite management through fireside chats, one‑on‑one and small group meetings. Severson explains what sets this conference apart: analyst‑led conversations focused on strategy, competitive positioning, and the business drivers that matter. He also covers the open‑access format, available company primers, and how investors can follow up after the event.

Send us Fan Mail

On this episode of the WTR Small‑Cap Spotlight, James Kisner, Technology Analyst at Water Tower Research, joins Tim Gerdeman, Vice Chair, Co‑Founder, and Chief Marketing Officer of Water Tower Research, to discuss the latest insights from WTR’s suite of AI research products. Kisner walks through key themes from the newest AI Flow Newsletter, describing what he calls a “whiplash” month — from viral bear‑case essays and a 4,000‑person layoff explicitly citing AI, to OpenAI’s record‑breaking $110B capital raise and the Pentagon’s unprecedented supply‑chain risk designation for Anthropic.

He also breaks down the AI Flow Index, which tracks the stock performance of roughly 400 public companies and shows a striking five‑month divergence: semiconductors up nearly 60% since launch while software has declined about 26%. Kisner then introduces the new AI Flow Private Pools Newsletter, which tracks approximately 45 private AI companies with a combined market value of about $1.73 trillion, highlighting notable valuation shifts — including Anthropic’s standout $92 billion single‑month gain.

Send us Fan Mail

Robert Sassoon, WTR Senior Healthcare Analyst, joins Tim Gerdeman to discuss obstructive sleep apnea (OSA) and the rapidly evolving treatment landscape for this widespread yet often undiagnosed and potentially fatal condition. The conversation explores the shift away from CPAP amid high non‑adherence rates toward emerging alternatives, including neurostimulation, pharmacotherapy, and oral appliances. Sassoon also highlights the valuation gap between incumbents such as ResMed (NYSE: RMD) and innovators like Vivos Therapeutics (NASDAQ: VVOS), whose approach extends beyond symptom management to address finite anatomical correction.